Compare · HAE vs MDLN
HAE vs MDLN
Side-by-side comparison of Haemonetics Corporation (HAE) and Medline Inc. (MDLN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both HAE and MDLN operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- MDLN is the larger of the two at $45.04B, about 9.1x HAE ($4.95B).
- MDLN has been more active in the news (12 items in the past 4 weeks vs 7 for HAE).
- Both have 25 recent analyst ratings on file.
- Company
- Haemonetics Corporation
- Medline Inc.
- Price
- -
- -
- Market cap
- $4.95B
- $45.04B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 1991
- 2025
- News (4w)
- 7
- 12
- Recent ratings
- 25
- 25
Haemonetics Corporation
Haemonetics Corporation, a healthcare company, provides medical products and solutions. It operates through three segments: Plasma, Blood Center, and Hospital. The company offers automated plasma collection devices, related disposables, and software, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx and El-Dorado Donor donation and blood unit management systems; Hemasphere software that provides support for blood drive planning; and Donor Doc and e-Donor software to enhance the donor recruitment and retention. In addition, the company offers hospital products comprising TEG diagnostic systems that enables clinicians to assess the coagulation status of a patient at the point-of-care or laboratory setting; TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions; Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and BloodTrack, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. It markets and sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.
Latest HAE
- AZENTA ANNOUNCES LEADERSHIP TRANSITION
- Haemonetics Corporation filed SEC Form 8-K: Regulation FD Disclosure
- SEC Form S-8 filed by Haemonetics Corporation
- SEC Form 10-Q filed by Haemonetics Corporation
- Haemonetics Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Haemonetics Corporation Announces First Quarter Fiscal 2027 Financial Results Available on Investor Relations Website
- New Study Offers Additional Evidence for the VASCADE MVP® XL System's Effectiveness in Electrophysiology Procedures with Large Bore Sheaths
- Director Madaus Martin D was granted 2,538 shares (SEC Form 4)
- Director Zane Ellen M was granted 2,538 shares, increasing direct ownership by 13% to 21,911 units (SEC Form 4)
- Director Pomeroy Claire was granted 2,538 shares, increasing direct ownership by 15% to 19,410 units (SEC Form 4)
Latest MDLN
- SEC Form 4 filed by Chief Executive Officer Boyle James M
- SEC Form 4 filed by Chief Operating Officer Miller Stephen L
- Large owner Gic Private Ltd sold $57,280,000 worth of shares (1,600,000 units at $35.80) (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13G/A filed by Medline Inc.
- Large owner Gic Private Ltd sold $21,002,305 worth of shares (590,284 units at $35.58) (SEC Form 4)
- Large owner Mozart Holdco, Inc. converted options into 500,000 shares and disposed of 500,000 units of Class B Common Stock, increasing direct ownership by 81,083% to 233,520,656 units (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13G/A filed by Medline Inc.
- Large owner Gic Private Ltd sold $79,971,448 worth of shares (2,248,612 units at $35.56) (SEC Form 4)
- SEC Form SCHEDULE 13G filed by Medline Inc.
- SEC Form 10-Q filed by Medline Inc.